GENFIT to Present New ACLF Research at EASL Congress 2024

May 29, 2024 - Lille, France - GENFIT, a biopharmaceutical company listed on Nasdaq and Euronext under the ticker GNFT, will be significantly represented at the EASL (European Association for the Study of the Liver) Congress 2024. The company, which is in late-stage development, is focused on improving treatments for rare and severe liver diseases, such as Acute-on-Chronic Liver Failure (ACLF).

Partnership Event with EF CLIF

At the Congress, GENFIT will launch a research collaboration with the European Foundation for the Study of Chronic Liver Failure (EF CLIF). This event will mark the beginning of their combined efforts to enhance the understanding of ACLF. EF CLIF has already conducted extensive observational studies across Europe and Latin America, which have been crucial in understanding the progression of cirrhosis and ACLF.

Professor Richard Moreau of EF CLIF expressed enthusiasm about the collaboration, emphasizing the potential to advance ACLF research and discover new treatment methods. GENFIT’s Chief Scientific Officer, Dean Hum, underscored the importance of having patient voices heard, with contributions from both the Global Liver Institute (GLI) and the European Liver Patients' Association (ELPA).

Notable Speakers and Presentations

Key speakers at the event will include:
- Richard Moreau, Director of EF CLIF
- Pascal Prigent, CEO of GENFIT
- Dean Hum, Chief Scientific Officer of GENFIT
- Donna R. Cryer, Founder and CEO of GLI
- Milan Mishkovikj, ELPA Board Member

The company will present findings from two significant research programs during the Congress:

Poster #1: Blood and Peritoneal Metabolomics
- Poster Code: THU-088
- Authors: Tyc, O.; Uschner, E. F.; Trebicka, J. et al
- Session: Cirrhosis and its Complications: ACLF and Critical Illness

Poster #2: Nitazoxanide and Liver Protection
- Poster Code: WED-105
- Authors: Staels, B.; Bobowski-Gerard, M. et al
- Session: Cirrhosis and its Complications: Experimental and Pathophysiology

UNVEIL-IT® and Other Events

GENFIT will also host an UNVEIL-IT® Investigator Meeting, bringing together key opinion leaders, investigators, and study team members to discuss the ongoing Phase 2 trial of VS-01. This meeting aims to provide insights and share experiences among investigators.

An educational event by ELPA will also feature GENFIT's ACLF programs. This training session aims to increase patient awareness about new drug innovations and advancements in medical treatments. ELPA's mission is to advocate for liver disease patients and ensure high standards of care across Europe.

About the EASL Congress

The EASL Annual Congress is a major international event in the field of liver disease, drawing more than 7,000 professionals from various sectors, including clinicians, researchers, and patient advocates. The four-day congress offers hands-on learning sessions and networking opportunities, allowing participants to engage with top experts in hepatology.

Understanding ACLF

ACLF is a syndrome characterized by liver and other organ failures, often resulting from an acute event like an infection in patients with pre-existing liver cirrhosis. It carries a high short-term mortality rate, with estimates indicating a significant patient population in the US, EU4, and UK. The incidence is rising due to factors such as aging populations, increased prevalence of liver diseases, diabetes, obesity, and alcohol consumption.

About GENFIT

GENFIT is dedicated to developing treatments for rare and serious liver diseases. The company has a robust R&D portfolio, including five ACLF-focused assets and other programs targeting conditions like cholangiocarcinoma, urea cycle disorder, and organic acidemia. GENFIT has successfully advanced therapies like elafibranor for Primary Biliary Cholangitis and continues to innovate in diagnostic tools. Headquartered in Lille, France, with offices in Paris, Zurich, and Cambridge, MA, GENFIT is committed to transforming liver disease treatment paradigms.

In summary, GENFIT's involvement in the EASL Congress 2024 highlights its dedication to advancing ACLF research and improving patient outcomes through collaboration, innovation, and education.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!